Brief: Mereo Biopharma Reports Interim Data From Study Of Etigilimab Anti-Tigit Antibody In Combination With Nivolumab In Solid Tumors

Mereo BioPharma

30/11/2021 12:50

Nov 30 (Reuters) - Mereo Biopharma Group PLC  MAH0y.F :
    * MEREO BIOPHARMA REPORTS INTERIM DATA FROM ACTIVATE PHASE
1B/2
OPEN LABEL STUDY OF ETIGILIMAB ANTI-TIGIT ANTIBODY IN
COMBINATION WITH NIVOLUMAB IN SOLID TUMORS
    * MEREO BIOPHARMA GROUP PLC - ONE COMPLETE RESPONSE, ONE
PARTIAL
RESPONSE AND FOUR CASES OF STABLE DISEASE OBSERVED AMONG 15
PATIENTS
    * MEREO BIOPHARMA GROUP PLC - ETIGILIMAB WAS WELL TOLERATED
WITH A
FAVORABLE SAFETY PROFILE
    * MEREO BIOPHARMA GROUP PLC - CLINICAL BENEFIT ALSO OCCURRED
IN
TUMOR TYPES WITH HISTORICALLY LOW RESPONSE RATES TO
ANTI-PD-1/PDL-1 ANTIBODIES

Source text for Eikon:  ID:nGNX4PgK2f 
Further company coverage:  MAH0y.F 

 ((Reuters.Briefs@thomsonreuters.com;))